Intersect Ent.

Intersect Ent. specialises in paranasal sinus spacers, primarily used in sinus augmentation procedures. Their portfolio includes implant systems like the Propel and Propel Mini series, which come in various configurations (e.g., with straight delivery systems) to create space within the sinus cavity for bone grafting and tissue regeneration. These devices support reconstructive sinus surgery by maintaining separation and promoting healing in the targeted area.

Intersect Ent. is based in the United States, which means its devices fall under the jurisdiction of the FDA (U.S. Food and Drug Administration). Since the company operates within the US market, its products must comply with FDA regulations, including classification as either Class I (generally lower risk) or Class III (higher risk, requiring stricter scrutiny). This regulatory framework ensures that devices meet safety and effectiveness standards before authorisation.

Intersect Ent.’s devices are registered in the FDA’s official databases, including the 510(k) Premarket Notification registry for lower-risk Class I or Class II devices (though their devices are primarily Class I or III), the Premarket Approval (PMA) registry for high-risk Class III products, and the Unique Device Identification (UDI) system. These registries track device authorisation pathways, classifications, and compliance with FDA requirements.

Intersect Ent.’s devices are classified as either Class I (generally simple, low-risk products with minimal regulatory oversight) or Class III (higher-risk devices requiring rigorous premarket approval due to potential life-threatening risks or lack of adequate performance data). The classification determines the regulatory pathway: Class III devices (e.g., some sinus implants) require a Premarket Approval Application (PMA), while Class I devices may only need a 510(k) notification or general controls. This classification ensures appropriate scrutiny based on the device’s risk profile.

The FDA’s Unique Device Identification (UDI) system assigns a distinct, machine-readable identifier (like a barcode or data matrix) to each device to improve tracking, transparency, and post-market surveillance. Listing under UDI ensures that Intersect Ent.’s devices can be uniquely traced in medical records, recalls, or regulatory databases, enhancing patient safety and compliance with FDA requirements. This system helps healthcare providers and regulators quickly verify device details, such as manufacturer, model, and batch, if needed.